London, United Kingdom
Isomorphic Labs is a promising venture aiming to revolutionize the pharmaceutical industry by integrating artificial intelligence into drug discovery. Founded in 2021 and based in the United Kingdom, they are leveraging their groundbreaking AlphaFold technology to reimagine drug design fundamentally.
By bringing together an interdisciplinary team, Isomorphic Labs has developed a cutting-edge drug design engine described as being capable of transformative impacts on medicine. The company's ambitious mission is to eventually solve all disease, highlighting their bold vision for the future of healthcare.
Most recently, the company raised a significant $600 million in a Series Unknown investment round on 24 April 2026. While investor specifics were not disclosed, this financial backing underscores the confidence in their AI-first approach to drug discovery. Overall, Isomorphic Labs represents a high-potential opportunity for investors looking to support pioneering advancements in health and biotechnology.
Deargen
Vilya